Transcription factor FOXA2-centered transcriptional regulation network in non-small cell lung cancer.

Lung cancer is the leading cause of cancer-mediated death. Although various therapeutic approaches are used for lung cancer treatment, these mainly target the tumor suppressor p53 transcription factor, which is involved in apoptosis and cell cycle arrest. However, p53-targeted therapies have limited application in lung cancer, since p53 is found to be mutated in more than half of lung cancers. In this study, we propose tumor suppressor FOXA2 as an alternative target protein for therapies against lung cancer and reveal a possible FOXA2-centered transcriptional regulation network by identifying new target genes and binding partners of FOXA2 by using various screening techniques. The genes encoding Glu/Asp-rich carboxy-terminal domain 2 (CITED2), nuclear receptor subfamily 0, group B, member 2 (NR0B2), cell adhesion molecule 1 (CADM1) and BCL2-associated X protein (BAX) were identified as putative target genes of FOXA2. Additionally, the proteins including highly similar to heat shock protein HSP 90-beta (HSP90A), heat shock 70 kDa protein 1A variant (HSPA1A), histone deacetylase 1 (HDAC1) and HDAC3 were identified as novel interacting partners of FOXA2. Moreover, we showed that FOXA2-dependent promoter activation of BAX and p21 genes is significantly reduced via physical interactions between the identified binding partners and FOXA2. These results provide opportunities to understand the FOXA2-centered transcriptional regulation network and novel therapeutic targets to modulate this network in p53-deficient lung cancer.

[1]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[2]  D. Sullivan,et al.  Nuclear export of proteins and drug resistance in cancer. , 2012, Biochemical pharmacology.

[3]  Jun Yu,et al.  CITED2 is a novel direct effector of peroxisome proliferator‐activated receptor γ in suppressing hepatocellular carcinoma cell growth , 2013, Cancer.

[4]  Ju-Seog Lee,et al.  Systems-level analysis of gene expression data revealed NR0B2/SHP as potential tumor suppressor in human liver cancer , 2010, Molecules and cells.

[5]  Y. Murakami,et al.  Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer , 2012, Breast Cancer.

[6]  M. Meyerson,et al.  Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. , 2012, Lung Cancer.

[7]  J. Gitlin,et al.  Role of hepatocyte nuclear factor-3 alpha and hepatocyte nuclear factor-3 beta in Clara cell secretory protein gene expression in the bronchiolar epithelium. , 1995, The Biochemical journal.

[8]  Jeffrey A Whitsett,et al.  Foxa2 is required for transition to air breathing at birth. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  K. Kaestner,et al.  The Foxa family of transcription factors in development and metabolism , 2006, Cellular and Molecular Life Sciences CMLS.

[10]  R. Lauro,et al.  The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis , 1994, Molecular and cellular biology.

[11]  M. Ebert,et al.  Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2. , 2012, Gastroenterology.

[12]  Janet Rossant,et al.  Microarray analysis of Foxa2 mutant mouse embryos reveals novel gene expression and inductive roles for the gastrula organizer and its derivatives , 2008, BMC Genomics.

[13]  Bas J. Wouters,et al.  A Transcriptional Profiling Study of CCAAT/Enhancer Binding Protein Targets Identifies Hepatocyte Nuclear Factor 3β as a Novel Tumor Suppressor in Lung Cancer , 2004, Cancer Research.

[14]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[15]  M. Stoffel,et al.  Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. , 2006, Cell metabolism.

[16]  J. Whitsett,et al.  Hepatocyte nuclear factor 3 activates transcription of thyroid transcription factor 1 in respiratory epithelial cells , 1996, Molecular and cellular biology.

[17]  B. Freidlin,et al.  Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[19]  Chul-Hong Kim,et al.  The expression of p21 is upregulated by forkhead box A1/2 in p53‐null H1299 cells , 2014, FEBS letters.

[20]  S. Calderwood,et al.  Molecular chaperones in mammary cancer growth and breast tumor therapy , 2012, Journal of cellular biochemistry.

[21]  G. Draetta,et al.  Role for Histone Deacetylase 1 in Human Tumor Cell Proliferation , 2007, Molecular and Cellular Biology.

[22]  Akira Mogi,et al.  TP53 Mutations in Nonsmall Cell Lung Cancer , 2011, Journal of biomedicine & biotechnology.

[23]  C. Witt,et al.  BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer , 2002, European Respiratory Journal.

[24]  M. Katoh,et al.  Human FOX gene family (Review). , 2004, International journal of oncology.

[25]  Jianguo Song,et al.  FOXA2 functions as a suppressor of tumor metastasis by inhibition of epithelial-to-mesenchymal transition in human lung cancers , 2011, Cell Research.

[26]  K. Kaestner,et al.  Six members of the mouse forkhead gene family are developmentally regulated. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Peter White,et al.  Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress , 2008, Nature Medicine.